Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript Summary
Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript Summary
The following is a summary of the Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript:
以下是Vivos Therapeutics, Inc. (VVOS) Q2 2024業績會的摘要:
Financial Performance:
金融業績:
Vivos Therapeutics reported notable Q2 2024 total revenue of $4.1 million, marking a 19% increase sequentially and year-over-year.
Gross profit for Q2 2024 was $2.7 million with a gross margin of 65%, showing an improvement from 62% in the comparable period in 2023.
Net loss significantly decreased by 65% to $1.9 million in Q2 2024 compared to the same period last year.
Vivos Therapeutics報告了Q2 2024總營業收入410萬美元,環比和同比分別增長19%。
Q2 2024的毛利潤爲270萬美元,毛利率爲65%,較2023年同期的62%有所改善。
與去年同期相比,Q2 2024的淨虧損大幅下降了65%,降至190萬美元。
Business Progress:
業務進展:
Vivos Therapeutics has seen an increased enrollment in its VIP program and an expansion in strategic alliances, including a notable collaboration with a multicenter sleep clinic operation in Colorado.
The company has improved cost structure and significantly reduced its cash burn, continuing efforts to achieve cash flow positive operations.
Recent FDA clearance to treat severe OSA using their oral appliances has potentially broadened their market.
Vivos Therapeutics的VIP計劃招生人數增加,並與科羅拉多州的一個多中心睡眠診所開展了重要的合作。
該公司改善了成本結構,並大幅減少了現金流失,繼續努力實現正現金流的運營。
最近通過FDA認可使用他們的口腔設備治療嚴重的阻塞性睡眠呼吸暫停,可潛在擴大市場。
Opportunities:
機會:
The strategic alliance with multicenter sleep clinics and the ability to address a broader range of OSA patients with FDA-approved treatment options positions Vivos for a potentially substantial increase in patient referrals and revenue.
與多中心睡眠診所的戰略聯盟以及能夠使用經FDA批准的治療選擇治療更廣泛範圍的阻塞性睡眠呼吸暫停患者的能力,使Vivos可以爲患者提供更多的轉診和獲取更多營業收入的機會。
Risks:
風險:
The success of new strategic alliances and the ongoing restructure pose execution risks, and the need to balance cost-cutting while scaling operations could impact operational stability.
新的戰略聯盟的成功和進行中的重組存在執行風險,並且在平衡成本削減和擴大運營之間需要權衡,可能會影響運營穩定性。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由AI生成。文章內容的準確性無法完全保證。有關更全面的詳細信息,請參閱IR網站。本文只是爲投資者提供參考,沒有任何指導或推薦建議。